methotrexate orion tablets 2.5 mg
orion pharma (sg) pte. ltd. - methotrexate disodium eqv methotrexate - tablet - methotrexate disodium eqv methotrexate 2.5mg
merex 2.5-methotrexate tablets usp 2.5 mg
accord healthcare private limited - methotrexate disodium eqv to methotrexate - tablet - methotrexate disodium eqv to methotrexate 2.5 mg
pms-methotrexate tablet
pharmascience inc - methotrexate (methotrexate disodium) - tablet - 2.5mg - methotrexate (methotrexate disodium) 2.5mg - antineoplastic agents
methotrexate
rosemont pharmaceuticals ltd - methotrexate disodium - oral solution - 2 mg/ml - methotrexate - antineoplastic and immunomodulating agents, antimetabolites, folic acid analogues - it is indicated in the following oncological indications: the maintenance treatment of acute lymphocytic leukaemia (all) in children and adults; the treatment of malignant trophoblastic tumours and for the treatment of severe active rheumatoid arthritis in adults and the treatment of severe forms of psoriasis vulgaris including chronic plaque psoriasis, erythrodermic psoriasis, psoriatic arthritis and pustular psoriasis which are not responsive to other conventional therapies such as phototherapy, puva and retinoids.
m-methotrexate tablet
mantra pharma inc - methotrexate (methotrexate disodium) - tablet - 2.5mg - methotrexate (methotrexate disodium) 2.5mg
dbl methotrexate injection bp 1 g10 ml
pfizer private limited - methotrexate sodium eqv methotrexate - injection - 1 g/10 ml - methotrexate sodium eqv methotrexate 1 g/10 ml
dbl methotrexate injection bp 50 mg2 ml (without preservative)
pfizer private limited - methotrexate sodium eqv methotrexate - injection - 50 mg/2 ml - methotrexate sodium eqv methotrexate 50 mg/2 ml
methotrexate- methotrexate sodium injection, solution
fresenius kabi usa, llc - methotrexate sodium (unii: 3ig1e710zn) (methotrexate - unii:yl5fz2y5u1) - methotrexate 25 mg in 1 ml - methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. in acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous t cell lymphoma), and lung cancer, particularly squamous cell and small cell types. methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-hodgkin’s lymphomas. methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. methotrexate is indicated in the symptomatic control of se
methotrexate sodium- methotrexate sodium injection, solution
sandoz inc - methotrexate sodium (unii: 3ig1e710zn) (methotrexate - unii:yl5fz2y5u1) - methotrexate 25 mg in 1 ml - methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. in acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. methotrexate is also indicated in the treatment of meningeal leukemia. methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous t cell lymphoma), and lung cancer, particularly squamous cell and small cell types. methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-hodgkin's lymphomas. methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection
methotrexate injection, solution
physicians total care, inc. - methotrexate (unii: yl5fz2y5u1) (methotrexate - unii:yl5fz2y5u1) - methotrexate 25 mg in 1 ml - methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. in acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. methotrexate is also indicated in the treatment of meningeal leukemia. methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous t cell lymphoma), and lung cancer, particularly squamous cell and small cell types. methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-hodgkin’s lymphomas. methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection